fashion -WSS

fashion

author：focus 2025-09-28 13:23:47 - browse：288

Adam's take main illustration — Molly Ferguson/STAT

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study.

A looming test for neoantigen cancer vaccines

Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that is resistant to immunotherapies like PD-1/PD-L1 inhibitors.

The Gritstone vaccine is designed to train a patient’s own T cells to recognize and kill cancer cells by targeting mutated cancer proteins, called neoantigens, that are unique to a patient’s own tumor. It’s a relatively new approach for cancer vaccines — made possible by powerful and relatively inexpensive genomic sequencing of tumors – that is intended to overcome all the previous failures in the field. Gritstone’s effort is also similar to one being used by Moderna and Merck that has reported encouraging results in melanoma — and is now being investigated in a Phase 3 study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： South Korea throws huge K

entertainment

WSS

NIH fellows want a pay raise. Will that mean less money for grants?

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Wegovy’s successful heart trial raises vital question about weight loss

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Iowa House, Senate pass 6

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Wikipedia

fashion

A looming test for neoantigen cancer vaccines

focus

What does generative AI mean for health care? We asked experts

What to know about OceanGate, the company behind the missing Titanic submersible

Novavax promises a turnaround & Lilly roils the obesity market

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why ADHD is under

The cancer drug shortage isn’t new — and neither are the solutions

It's time to get medical device identifiers over the finish line

United colonoscopy coverage change 'may cost lives,' doctors say

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

knowledge

HCA discloses massive data breach affecting 11 million patients

Naloxone nonprofit donates 200,000 doses after FDA approval

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Naloxone nonprofit donates 200,000 doses after FDA approval

NIH fellows want a pay raise. Will that mean less money for grants?

What to know about OceanGate, the company behind the missing Titanic submersible

entertainment

hotspot

explore

Wikipedia